Journal of Clinical Oncology
Articles in this Issue
Clinical validation of a metabolomics-based multi-cancer early detection test.
e22512 Background: Multi-cancer detection (MCD) tests can improve the efficacy of existing screening tests by detecting a...
Applying a large language model to detect immune-related adverse events in electronic health records: Effect of integrating prescription and laboratory data on accuracy.
12133 Background: Accurate identification of immune-related adverse events (irAEs) is essential; however, manual review of...
Zelenectide pevedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1.
4563 Background: Zelenectide pevedotin (zele, formerly BT8009) is a highly selective Bicycle Drug Conjugate (BDC) targetin...
Photodynamic Therapy Combined with Biliary Drainage for Extrahepatic Cholangiocarcinoma: A propensity score–matched, single-center retrospective study.
e16279 Background: Inoperable extrahepatic cholangiocarcinoma (eCCA) carries a poor prognosis. This study evaluates the ef...
Incidence and risk of musculoskeletal and rheumatologic (MSK-R) immune-related adverse events (irAEs) in a large real-world cohort.
e23409 Background: Immunotherapy (IT) improves cancer outcomes but is associated with irAEs, including MSK-R toxicities, w...
National trends in mortality from gastric cancer with metastatic involvement of the digestive and respiratory systems in the United States.
e15694 Background: Gastric cancer remains a major contributor to cancer-related mortality in the United States (US), parti...
Clinical efficiency of remote symptom monitoring using electronic patient-reported outcome (ePRO) in lung cancer: Results of the prospective, multicenter REAL-MOOV-LUNG trial.
11107 Background: Remote symptom monitoring using electronic patient-reported outcome (ePRO) has been shown to provide cli...
A retrospective analysis of outcomes in metastatic solid tumors harboring alterations in the PI3K pathway as stratified by the presence or absence of diseases of insulin resistance.
e22668 Background: Epidemiologic links are established between diseases of insulin resistance/hyperinsulinemia [pre-diabet...
Quality of life analysis from a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 versus radium-223 in metastatic castration-resistant prostate cancer with bone metastases (COMRADE).
5040 Background: Radium-223 is an α-emitting radioisotope that improves overall survival in men with metastatic castration...
Real-world study of adebrelimab for immune resumption after immune-related adverse events (irAEs).
e23334 Background: "Management of Immunotherapy-Related Toxicities. NCCN Guidelines V2.2024" suggests considering restarti...
AI-enabled clinical trial framework for end-to-end site recommendation and enrollment projection.
11022 Background: Reliable accrual forecasting is essential in oncology trials because delayed enrollment reduces statisti...
Renal function eligibility in multiple myeloma CAR T and bispecific antibody clinical trials.
e19528 Background: Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) have transformed the t...
Barriers to radiotherapy access and workflow efficiency in a resource-limited tertiary center: A real-world analysis from Bangladesh.
e13638 Background: Bangladesh faces a rapidly increasing cancer burden, with GLOBOCAN 2022 estimating nearly 167,000 new c...
Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC).
3505 Background: Antibody-drug conjugate (ADC) targeting HER2 represents standard therapy for HER2-positive gastric cancer...
Volrustomig monotherapy for recurrent/metastatic HNSCC: Substudy 2 of the eVOLVE-02 phase 2 study.
6025 Background: Inhibition of PD-1 is an important part of standard of care treatment options for patients (pts) with rec...
Outcome of adjuvant BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600K– compared to V600E-mutated melanoma.
9576 Background: Patients with resected stage III BRAF V600 mutated melanoma can be treated with combined dabrafenib and t...
Real-world outcomes of doxorubicin plus trabectedin (D+T) in leiomyosarcoma (LMS).
e23536 Background: LMS-04 trial shows improved progression-free survival (PFS), overall survival (OS), and objective respo...
Clonal hematopoiesis and cardiovascular outcomes after hematopoietic cell transplantation: A systematic review and meta-analysis.
e18578 Background: Clonal hematopoiesis (CH) is a known risk factor for cardiovascular disease, but its impact in cancer p...
A multicenter randomized phase III study for newly diagnosed, maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide versus chemoradiotherapy alone: Japan Clinical Oncology Group study JCOG1703 (MACS study).
2001 Background: Three randomized phase III trials evaluated carmustine wafers (CWs) before temozolomide (TMZ) became stan...
Differential impact of venous thromboembolism and metastatic disease on in-hospital mortality and 30-day readmission in pancreatic cancer: A Nationwide Readmissions Database analysis.
e16445 Background: Pancreatic cancer is associated with a high incidence of venous thromboembolism (VTE), early mortality,...
Drivers of clinician engagement in oncology trial accrual within an IMC in Shanghai: A mixed-methods study.
e23034 Background: Recruitment shortfalls frequently delay oncology clinical trials. Integrated medical consortia (IMCs) m...
Latent transitions of distress risk during cancer treatment and their concordance with anxiety, depression, and quality of life in a large multicenter cohort.
11106 Background: Distress is prevalent in patients with cancer and may change throughout treatment. However, longitudinal...
Neoadjuvant cemiplimab plus cetuximab prior to salvage surgery for recurrent oral cavity squamous cell carcinoma.
TPS6136 Background: Locoregional recurrence of oral cavity squamous cell carcinoma (OCSCC) after curative-intent therapy r...
Time-dependent recurrence risk stratification after neoadjuvant chemotherapy for risk-adapted surveillance in breast cancer.
e12672 Background: Post-treatment surveillance after neoadjuvant chemotherapy (NAC) is largely uniform and does not accoun...
Association of angiogenic, fibrotic, and immunosuppressive tumor microenvironment with immunotherapy outcomes in metabolic disease–associated biliary tract cancers.
e16004 Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing risk factor for bilia...